你即將離開本站

並前往https://www.astrazeneca-us.com/media/press-releases/2022/lynparza-olaparib-plus-abiraterone-reduced-risk-of-disease-progression-by-34-vs-standard-of-care-in-1st-line-metastatic-castration-resistant-prostate-cancer-02142022.html

LYNPARZA® (olaparib) plus abiraterone ... - AstraZeneca US

irrespective of homologous recombination repair gene mutations ... a deleterious or suspected deleterious BRCA mutation, and/or ...

確定！ 回上一頁

查詢 「Deleterious mutation」的人也找了：

  1. deleterious mutation中文
    2.